172 related articles for article (PubMed ID: 34424319)
1. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.
Pemmaraju N; Carter BZ; Bose P; Jain N; Kadia TM; Garcia-Manero G; Bueso-Ramos CE; DiNardo CD; Bledsoe S; Daver NG; Popat U; Konopleva MY; Zhou L; Pierce S; Estrov ZE; Borthakur GM; Ohanian M; Qiao W; Masarova L; Wang X; Mak PY; Cortes J; Jabbour E; Verstovsek S
Blood Adv; 2021 Aug; 5(16):3163-3173. PubMed ID: 34424319
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.
Gowin K; Kosiorek H; Dueck A; Mascarenhas J; Hoffman R; Reeder C; Camoriano J; Tibes R; Gano K; Palmer J; Mesa R
Leuk Res; 2017 Sep; 60():31-35. PubMed ID: 28646676
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
[TBL] [Abstract][Full Text] [Related]
5. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
Shekhar TM; Burvenich IJG; Harris MA; Rigopoulos A; Zanker D; Spurling A; Parker BS; Walkley CR; Scott AM; Hawkins CJ
BMC Cancer; 2019 Sep; 19(1):924. PubMed ID: 31521127
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J; Migliaccio AR; Kosiorek H; Bhave R; Palmer J; Kuykendall A; Mesa R; Rampal RK; Gerds AT; Yacoub A; Pettit K; Talpaz M; Komrokji R; Kremyanskaya M; Gonzalez A; Fabris F; Johnson K; Dougherty M; McGovern E; Arango Ossa J; Domenico D; Farnoud N; Weinberg RS; Kong A; Najfeld V; Vannucchi AM; Arciprete F; Zingariello M; Falchi M; Salama ME; Mead-Harvey C; Dueck A; Varricchio L; Hoffman R
Clin Cancer Res; 2023 Sep; 29(18):3622-3632. PubMed ID: 37439808
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
[TBL] [Abstract][Full Text] [Related]
9. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
Tefferi A; Cervantes F; Mesa R; Passamonti F; Verstovsek S; Vannucchi AM; Gotlib J; Dupriez B; Pardanani A; Harrison C; Hoffman R; Gisslinger H; Kröger N; Thiele J; Barbui T; Barosi G
Blood; 2013 Aug; 122(8):1395-8. PubMed ID: 23838352
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
[TBL] [Abstract][Full Text] [Related]
11. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Silver RT; Barel AC; Lascu E; Ritchie EK; Roboz GJ; Christos PJ; Orazi A; Hassane DC; Tam W; Cross NCP
Cancer; 2017 Jul; 123(14):2680-2687. PubMed ID: 28518222
[TBL] [Abstract][Full Text] [Related]
12. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA
Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923
[TBL] [Abstract][Full Text] [Related]
15. Targeting inhibitors of apoptosis in oral squamous cell carcinoma in vitro.
Scheurer MJJ; Seher A; Steinacker V; Linz C; Hartmann S; Kübler AC; Müller-Richter UDA; Brands RC
J Craniomaxillofac Surg; 2019 Oct; 47(10):1589-1599. PubMed ID: 31387829
[TBL] [Abstract][Full Text] [Related]
16. Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment.
Frommann K; Appl B; Hundsdoerfer P; Reinshagen K; Eschenburg G
J Pediatr Surg; 2018 Oct; 53(10):2059-2064. PubMed ID: 29455885
[TBL] [Abstract][Full Text] [Related]
17. Induction of Necroptosis in Human Breast Cancer Drug-Resistant Cells by SMAC Analog LCL161 After Caspase Inhibition Requires RIP3.
Jin G; Liu Y; Xu P; Jin G
Pharmazie; 2019 Jun; 74(6):363-368. PubMed ID: 31138375
[TBL] [Abstract][Full Text] [Related]
18. OTUD7B suppresses Smac mimetic-induced lung cancer cell invasion and migration via deubiquitinating TRAF3.
Zhang B; Yang C; Wang R; Wu J; Zhang Y; Liu D; Sun X; Li X; Ren H; Qin S
J Exp Clin Cancer Res; 2020 Nov; 39(1):244. PubMed ID: 33198776
[TBL] [Abstract][Full Text] [Related]
19. The IAP Protein Family, SMAC Mimetics and Cancer Treatment.
Philchenkov A; Miura K
Crit Rev Oncog; 2016; 21(3-4):185-202. PubMed ID: 27915971
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Hexner EO; Mascarenhas J; Prchal J; Roboz GJ; Baer MR; Ritchie EK; Leibowitz D; Demakos EP; Miller C; Siuty J; Kleczko J; Price L; Jeschke G; Weinberg R; Basu T; Pahl HL; Orazi A; Najfeld V; Marchioli R; Goldberg JD; Silverman LR; Hoffman R
Leuk Lymphoma; 2015; 56(9):2543-51. PubMed ID: 25563429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
